Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume

Bone

Volumn 44, Issue 1, 2009, Pages 17-23

  Kellum, Ethan ^a   Starr, Harlan ^a   Arounleut, Phonepasong ^a   Immel, David ^b   Fulzele, Sadanand ^a   Wenger, Karl ^a   Hamrick, Mark W ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b SAVANNAH RIVER NATIONAL LABORATORY   (United States)

Author keywords

Activin; ActRIIB; BMP 2; Chondrogenesis; Osteogenesis

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR 2B; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN TYPE 1; MESSENGER RNA; MYOSTATIN; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX5; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DEVELOPMENT; BONE STRENGTH; CALLUS; CHONDROGENESIS; FEMALE; FIBULA FRACTURE; FIBULA OSTEOTOMY; FRACTURE; FRACTURE HEALING; GENE MUTATION; HISTOLOGY; IMAGING SYSTEM; LOADING TEST; MALE; MICRO-COMPUTED TOMOGRAPHY; MUSCLE GROWTH; MUSCLE MASS; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; SKELETAL MUSCLE;

ANIMALS; BIOMECHANICS; BONY CALLUS; CARTILAGE; FEMALE; FRACTURES, BONE; GENE EXPRESSION REGULATION; HETEROZYGOTE; MALE; MICE; MYOSTATIN; ORGAN SIZE; OSTEOTOMY; SOXD TRANSCRIPTION FACTORS; TIME FACTORS;

EID: 57449118268     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.08.126     Document Type: Article

References (27)

1. McPherron A.C., Lawler A.M., and Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387 (1997) 83-90
2. Schuelke M., Wagner K.R., Stolz L.E., Hubner C., Riebel T., Komen W., et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N. Eng. J. Med. 350 (2004) 2682-2688
3. Zimmers T.A., Davies M.V., Koniaris L.G., Haynes P., Esquela A., Tomkinson K., et al. Induction of cachexia in mice by systemically administered myostatin. Science 296 (2002) 1486-1488
4. Wagner K.R., Liu X., Chang X., and Allen R.E. Muscle regeneration in the prolonged absence of myostatin. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2519-2524
5. Hamrick M.W. Increased bone mineral density in the femora of GDF8 knockout mice. Anat. Rec. 272 (2003) 388-391
6. Hamrick M.W., Pennington C., and Byron C.D. Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J. Orthop. Res. 21 (2003) 1025-1032
7. Nicholson E.K., Stock S.R., Hamrick M.W., and Ravosa M.J. Biomineralization and adaptive plasticity of the temporomandibular joint in myostatin knockout mice. Arch. Oral Biol. 51 (2006) 37-49
8. Hamrick M.W., Shi X., Zhang W., Pennington C., Kang B., Thakore H., et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone 40 (2007) 1544-1553
9. Bialek P., Parkington J., Warner L., St. Andre M., Jian L., Gavin D., et al. Mice treated with a myostatin/GDF-8 decoy receptor, ActRIIB-Fc, exhibit a tremendous increase in bone mass. Bone 42 (2008) S46
10. Cho T., Gerstenfeld L., and Einhorn T. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J. Bone Miner. Res. 17 (2002) 513-520
11. Midura R.J., Ibiwoye M.O., Powell K.A., Sakai Y., Doehring T., Grabiner M., et al. Pulsed electromagnetic field treatments enhance the healing of fibular osteotomies. J. Orthop. Res. 23 (2005) 1035-1046
12. Hamrick M.W., Samaddar T., Pennington C., and McCormick J. Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J. Bone Miner. Res. 21 (2006) 477-483
13. Gerstenfeld L.C., Wronski T.J., Hollinger J.O., and Einhorn T. Application of histomorphometric methods to the study of bone repair. J. Bone Miner. Res. 20 (2005) 1715-1722
14. Hadjiargyrou M., Lombardo F., Zhao S., Ahrens W., Joo J., Ahn H., et al. Transcriptional profiling of bone regeneration. J. Biol. Chem. 277 (2002) 30177-30182
15. Artaza J., Bhasin S., Magee T., Reisz-Porszasz S., Shen R., Groome N., et al. Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multi-potent cells. Endocrinol. 146 (2005) 3547-3557
16. Lee S.J. Regulation of muscle mass by myostatin. Annu. Rev. Cell Dev. Biol. 20 (2004) 61-86
17. Smits P., Dy P., Mitra S., and Lefebvre V. Sox5 and sox 6 are needed to develop and maintain source, columnar, and hypertrophic chondrocytes in the cartilage growth plate. J. Cell Biol. 164 (2004) 747-758
18. Nagamine T., Imamura T., Ishidou Y., Kato M., Murata F., Dijke P., et al. Immunohistochemical detection of activin A, follistatin, and activin receptors during fracture healing in the rat. J. Orthop. Res. 16 (1998) 314-321
19. Sakai R., Miwa K., and Eto Y. Local administration of activin promotes fracture healing in the rat fibula fracture model. Bone 25 (1999) 191-196
20. Gaddy Kurten D., Coker J., Abe E., Jilka R., and Manolagas S. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 143 (2002) 74-83
21. Hirotani H., Ohtsuka-Isoya M., Mori S., Sakai R., Eto Y., Echigo S., et al. Activin A increases the mass of grafted bone in C3H/HeJ mice. Calcif. Tissue Int. 70 (2002) 330-338
22. Rebbapragada A., Benchabane H., Wrana J.L., Celeste A., and Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 23 (2003) 7230-7242
23. Ekaza D.J., and Cabello G. The myostatin gene: physiology and pharmacological relevance. Curr. Opin. Pharmacol. 7 (2002) 1-6
24. Bahamonde M.E., and Lyons K.M. BMP3: to be or not to be a BMP. J. Bone Jt. Surg. 83-A Suppl 1 (2001) S56-S62
25. Gamer L.W., Nove J., Levin M., and Rosen V. BMP-3 is a novel inhibitor of both activin and BMP-4 signaling in xenopus embryos. Dev. Biol. 285 (2005) 156-168
26. Piek E., Afrakhte M., Sampath K., van Zoelen E., Heldin C., and Dijke P. Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. J. Cell. Physiol. 180 (1999) 141-149
27. Bogdanovich S., Perkins K., Krag T., Whittemore L., and Khurana T. Myostatin-propeptide mediated amelioration of dystrophic pathophysiology. FASEB J. 19 (2005) 543-549